The purpose of this study is to evaluate the effects of multiple therapeutic and
supratherapeutic doses of KW-6356 on the QT interval corrected for heart rate in Japanese
healthy adults.
Phase:
Phase 1
Details
Lead Sponsor:
Kyowa Kirin Co., Ltd.
Treatments:
Moxifloxacin Norgestimate, ethinyl estradiol drug combination